Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.

Compounded vs Branded Semaglutide 2026: What’s Legal, What’s Safe, What’s Cheaper

Compounded vs Branded Semaglutide at a Glance

Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~10 min read

Compounded semaglutide remains legal in May 2026 only when prepared by 503A pharmacies under individual patient-specific prescriptions. Mass compounding ended after FDA removed semaglutide from the shortage list on February 21, 2025. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with public comments open through June 29, 2026. Branded Wegovy and Ozempic remain FDA-approved finished products.

The short answer: compounded semaglutide is still legal in May 2026, but the path is narrowing

If you are reading this in May 2026, here is the honest state of play. You can still get compounded semaglutide from a licensed telehealth platform that partners with a 503A compounding pharmacy. The medication is prepared per individual prescription, shipped to your door, and typically costs $99-$199 per month before consult fees. That part has not changed.

What has changed is the regulatory pressure. The FDA’s April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List is a clear signal that the agency wants large-scale outsourcing facilities out of the GLP-1 business. Comments are open through June 29, 2026, and a final rule could land later in the year. For 503A patient-specific compounding — the lane Mochi Health, Henry Meds, and Remedy Meds operate in — the legal basis remains, but it is under scrutiny.

For most patients in 2026, the practical question is no longer “is compounded legal?” but “is the cost gap worth the uncertainty?”

[provider=”mochi-health”]

Definitions: 503A patient-specific vs 503B bulk outsourcing facilities

The entire compounded GLP-1 debate hinges on two sections of the Federal Food, Drug, and Cosmetic Act (FDCA). Get these straight and the rest of the policy noise makes sense.

503A pharmacies are traditional compounding pharmacies. They prepare medications for individual patients with valid prescriptions. They are regulated primarily by state boards of pharmacy, not the FDA. They cannot make medications in advance for general distribution. Every vial is tied to a named patient.

503B outsourcing facilities are FDA-registered manufacturers that can produce compounded drugs in bulk without patient-specific prescriptions — but only from a limited list (the “503B Bulks List”) and only under tighter cGMP standards. During the 2022-2024 semaglutide and tirzepatide shortages, 503B facilities legally produced GLP-1s at scale because the active ingredients qualified for the “shortage exception.”

When the shortages ended, that exception collapsed. The April 30, 2026 proposal would formalize the exclusion — meaning even if shortages return, semaglutide and tirzepatide would not automatically become eligible for 503B mass compounding again.

Timeline: Feb 21 2025 delisting through April 30 2026 proposed Bulks List exclusion

What “compounded” actually means (and how it differs from FDA-approved Wegovy/Ozempic)

Branded Wegovy, Ozempic, Mounjaro, and Zepbound are FDA-approved finished drug products. Every batch is manufactured under strict cGMP (current Good Manufacturing Practice) standards. Identity, potency, purity, and sterility are validated. The drug device combination — pen, vial, dose — is the same product the agency approved during clinical trials.

Compounded semaglutide is something different. A 503A pharmacy starts with semaglutide active pharmaceutical ingredient (API) — sometimes the base form, sometimes salt forms like semaglutide sodium or semaglutide acetate that the FDA has explicitly flagged as not equivalent to the API used in Ozempic/Wegovy. The pharmacy reconstitutes that API with sterile diluent, often adding B-vitamins (B12 in particular) to make a custom formulation. The end product is a sterile injectable that resembles brand semaglutide but is not the same product, and it has never been through FDA premarket review.

That distinction matters because the FDA’s quality oversight tools — adverse event reporting, lot-level recalls, batch testing — work differently for compounded products. State boards of pharmacy enforce 503A compliance; the FDA inspects 503B outsourcing facilities. When something goes wrong with a compounded prescription, accountability is more diffuse.

Safety considerations: identity, potency, sterility, recent recalls

Compounded semaglutide is not inherently unsafe, but the safety floor is lower than for FDA-approved Wegovy because no premarket review confirms identity, potency, and sterility batch-by-batch. The FDA has flagged three specific concerns since 2024:

• Salt-form substitution: Some compounders used semaglutide sodium or acetate, which the FDA has stated are not the same as the API in Wegovy/Ozempic and may not be eligible for compounding at all.
• Dosing errors: The FDA has received reports of patients drawing 5x or 10x intended doses from compounded vials because concentrations vary by pharmacy and patients are unfamiliar with measuring units.
• Sterility: 503A pharmacies are not held to the same cGMP sterile manufacturing standards as FDA-registered manufacturers. Localized contamination events have triggered state-level recalls.

Most patients tolerate compounded semaglutide without incident, and reputable 503A pharmacies use independent labs for potency and sterility testing. But “most patients are fine” is a weaker claim than “this product was approved by the FDA.” Patients with comorbidities — especially diabetes, cardiovascular disease, or pregnancy — should weigh that gap carefully.

Cost comparison: compounded ~$99-$397/mo vs Wegovy ~$199-$349/mo NovoCare

In 2024, the cost gap was the whole story — compounded semaglutide at $199/month versus Wegovy retail at $1,349/month was not a close call for uninsured patients. In May 2026, that gap is dramatically narrower because Novo Nordisk and Eli Lilly responded.

The crossover point: if NovoCare’s $149-$199/month introductory pricing fits your dose, branded Wegovy is now within $30/month of the cheapest compounded option — and it is FDA-approved. The compounded value proposition is strongest for patients on higher doses ($349/mo ongoing NovoCare) or those who need tirzepatide and find Lilly’s $299-$449 vial pricing out of reach.

Which telehealth providers compound vs which use brand

The provider landscape sorted itself by spring 2026:

• Brand-only: Ro (Wegovy + Zepbound partner), Sequence/WeightWatchers Clinic (stopped compounding May 2025), Teladoc Health.
• Primarily compounded: Mochi Health (503A semaglutide and tirzepatide), Henry Meds (503A; also offers oral semaglutide), Remedy Meds (503A with some brand plans).
• Hybrid: Hers (brand-name Wegovy/Ozempic, with compounded only when clinically necessary), Form Health (brand-first).

If you read our best GLP-1 telehealth roundup for 2026, the brand-vs-compounded split is the single biggest filter to apply before comparing prices. A $99/month Mochi sticker is not directly comparable to a $349/month Ro Wegovy plan because the products are not the same drug.

[provider=”ro”]

The Eli Lilly v. Henry Meds lawsuit (April 2025) and ongoing litigation

In April 2025, Eli Lilly sued Henry Meds in federal court alleging false advertising and trademark issues tied to Henry’s marketing of compounded tirzepatide. The case is ongoing in 2026 and is widely watched as a template for further branded-manufacturer litigation. Lilly has also pursued enforcement against several other compounders and the FDA has issued multiple warning letters.

For patients, the lawsuit itself is less important than the trajectory it signals. Major compounders are pulling out of GLP-1s — ProRx and BPI Labs exited in early 2026 — and the remaining 503A operators face mounting legal and supply-chain risk. Continuity of supply is the real concern, not whether Henry Meds wins or loses in court.

If you’re currently on compounded: 3 decision paths

Path 1: Stay on compounded. If your provider is a stable 503A pharmacy, your weight loss is progressing, and you tolerate the medication, there is no urgent regulatory reason to switch in May 2026. Monitor the June 29, 2026 comment period close and any final rule that follows.

Path 2: Switch to branded Wegovy via NovoCare. If you qualify for the $149-$199/month introductory pricing (good through June 30, 2026) and your dose lands in the covered range, the cost gap is small enough that FDA approval status, manufacturer accountability, and supply certainty tip the calculus. See our Wegovy vs Zepbound cost guide for the annual TCO math.

Path 3: Switch to branded Zepbound vials. Lilly cut vial prices on February 23, 2026 to $299-$449/month. If you do better on tirzepatide than semaglutide and can keep the 45-day refill cadence, this is now competitive with compounded tirzepatide and offers FDA-approved supply.

If you’re starting fresh: branded vs compounded decision framework

New patients in May 2026 should default to branded unless cost is the binding constraint. The decision framework we use on our weight loss provider comparison:

1. Insurance check first. If your commercial plan covers Wegovy or Zepbound with a $25 savings card copay, the cost question is closed — go branded.
2. If uninsured, NovoCare/LillyDirect direct. $149-$449/month direct from manufacturer with FDA-approved product.
3. If those prices still do not fit, compounded 503A. Pick a provider with transparent pharmacy sourcing — see our Mochi Health review and Remedy Meds review for what to ask.
4. Avoid sources that cannot identify the 503A pharmacy dispensing your medication or that ship without a video consult and synchronous prescriber review.

Frequently Asked Questions

Sources

• FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize (verified May 2026)
• NovoCare Wegovy/Ozempic self-pay pricing (verified May 2026)
• Lilly Zepbound pricing (verified May 2026)
• FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List (April 30, 2026)
• Orrick: FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs (May 2026)
• Burr: FDA Removes Semaglutide From the Drug Shortage List (Feb 21, 2025)

Medical disclaimer: Information here is educational only. GLP-1 medications can cause serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Consult a licensed clinician before starting, switching, or stopping any prescription weight-loss medication.